Zhuolong Zhou,Kevin Van der Jeught,Yuanzhang Fang,Tao Yu,Yujing Li,Zheng Ao,Sheng Liu,Lu Zhang,Yang Yang,Haniyeh Eyvani,Mary L. Cox,Xiyu Wang,Xiaoming He,Guang Ji,Bryan P. Schneider,Feng Guo,Jun Wan,Xinna Zhang,Xiongbin Lu

Abstract:In breast cancer, genetic heterogeneity, the lack of actionable targets and immune evasion all contribute to the limited clinical response rates to immune checkpoint blockade therapy. Here, we report a high-throughput screen based on the functional interaction of mouse- or patient-derived breast tumour organoids and tumour-specific cytotoxic T cells for the identification of epigenetic inhibitors that promote antigen presentation and potentiate T-cell-mediated cytotoxicity. We show that the epigenetic inhibitors GSK-LSD1, CUDC-101 and BML-210, identified by the screen, display antitumour activities in orthotopic mammary tumours in mice, that they upregulate antigen presentation mediated by the major histocompatibility complex class I on breast tumour cells and that treatment with BML-210 substantially sensitized breast tumours to the inhibitor of the checkpoint programmed death-1. Standardized measurements of tumour-cell killing activity facilitated by tumour-organoid–T-cell screens may help with the identification of candidate immunotherapeutics for a range of cancers.

Author Correction: An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity

Author Correction: Targeted Inhibition of STAT/TET1 Axis As a Therapeutic Strategy for Acute Myeloid Leukemia

Author Correction to “Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy” [acta Pharm Sin B 12 (2022) 4224–4234]

An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity

Erratum: Author Correction to "Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy" [acta Pharm Sin B (2022) 4224-4234].

Author Correction: Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis

Author Correction: Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation

Author Correction: A Next-Generation Tumor-Targeting IL-2 Preferentially Promotes Tumor-Infiltrating CD8+ T-cell Response and Effective Tumor Control

Author Correction: CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia

Author Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T reg cells

Author Correction: CIS is a potent checkpoint in NK cell–mediated tumor immunity

Corrigendum: Anti-cancer immune effect of human colorectal cancer neoantigen peptide based on MHC class I molecular affinity screening

Author Correction: Crizotinib-induced immunogenic cell death in non-small cell lung cancer

Publisher Correction: Eliminating blood oncogenic exosomes into the small intestine with aptamer-functionalized nanoparticles.

Correction: Cytokine-induced killer cell delivery enhances the antitumor activity of oncolytic reovirus.

Author Correction to ‘bioengineered Mir-124-3p Prodrug Selectively Alters the Proteome of Human Carcinoma Cells to Control Multiple Cellular Components and Lung Metastasis in Vivo’ [acta Pharmaceutica Sinica B 11 (2021) 3950–3965]

Author Correction: Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis

Corrigendum to “A tumor cell membrane-coated self-amplified nanosystem as a nanovaccine to boost the therapeutic effect of anti-PD-L1 antibody” [Bioact. Mater. 21 299–312]

Correction: Intracellular regulation of zinc by metal–organic framework-mediated genome editing for prostate cancer therapy

Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Author Correction: Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours